|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
10/19/2005 5:12:44 PM
COLUMBIA, Md.--(BUSINESS WIRE)--Feb. 15, 2005--Hemagen Diagnostics, Inc. (OTCBB:HMGN.OB) a biotechnology company that develops, manufactures, and markets proprietary medical diagnostic test kits, today reported operating results for the first fiscal quarter ended December 31, 2004. For the three-month period ended December 31, 2004, the net loss was $235,000 or $(0.02) per share, compared to a net loss of $574,000 or ($0.06) per share for the period ended December 31, 2003. After adjusting for non-cash charges including depreciation, amortization, and non-cash interest, the net loss for the quarter ended December 31, 2004 was $103,000 compared to a net loss of $68,000 for the quarter ended December 31, 2003.
|
|
|
|
|
|
|
|
|
|
|